ATE495167T1 - Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors - Google Patents

Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors

Info

Publication number
ATE495167T1
ATE495167T1 AT06807495T AT06807495T ATE495167T1 AT E495167 T1 ATE495167 T1 AT E495167T1 AT 06807495 T AT06807495 T AT 06807495T AT 06807495 T AT06807495 T AT 06807495T AT E495167 T1 ATE495167 T1 AT E495167T1
Authority
AT
Austria
Prior art keywords
pyridazine
dopamine
antagonists
piperidine
receptor
Prior art date
Application number
AT06807495T
Other languages
English (en)
Inventor
Bruyn Marcel De
Gregor Macdonald
Ludo Kennis
Xavier Langlois
Den Keybus Frans Van
Roosbroeck Yves Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE495167T1 publication Critical patent/ATE495167T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06807495T 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors ATE495167T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05110028 2005-10-26
EP06100209 2006-01-10
EP06101545 2006-02-10
PCT/EP2006/067696 WO2007048779A1 (en) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE495167T1 true ATE495167T1 (de) 2011-01-15

Family

ID=35734993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06807495T ATE495167T1 (de) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors

Country Status (34)

Country Link
US (3) US8940743B2 (de)
EP (1) EP1943242B1 (de)
JP (1) JP5140598B2 (de)
KR (1) KR101351910B1 (de)
CN (1) CN101291925B (de)
AP (1) AP2607A (de)
AR (1) AR058151A1 (de)
AT (1) ATE495167T1 (de)
AU (1) AU2006307930B2 (de)
BR (1) BRPI0617787A2 (de)
CA (1) CA2623160C (de)
CR (1) CR10020A (de)
CY (1) CY1111977T1 (de)
DE (1) DE602006019624D1 (de)
DK (1) DK1943242T3 (de)
EA (1) EA015681B1 (de)
EC (1) ECSP088396A (de)
ES (1) ES2359020T3 (de)
GT (1) GT200800033A (de)
HN (1) HN2008000646A (de)
HR (1) HRP20110226T1 (de)
IL (1) IL191016A (de)
JO (1) JO2769B1 (de)
MY (1) MY145609A (de)
NO (1) NO20082350L (de)
NZ (1) NZ566785A (de)
PL (1) PL1943242T3 (de)
PT (1) PT1943242E (de)
RS (1) RS51674B (de)
SI (1) SI1943242T1 (de)
TW (1) TWI399373B (de)
UA (1) UA94058C2 (de)
WO (1) WO2007048779A1 (de)
ZA (1) ZA200803668B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP2010525013A (ja) * 2007-04-23 2010-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしてのピリジン誘導体
CA2683111A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 5−ht6受容体アンタゴニストとしての置換された6−(1−ピペラジニル)−ピリダジン類
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102171189B (zh) * 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US20180350708A1 (en) * 2017-06-06 2018-12-06 Powertech Technology Inc. Package structure and manufacturing method thereof
EP4574152A1 (de) 2023-12-22 2025-06-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kaliumkanalaktivatoren zur behandlung von epileptischen erkrankungen

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
US5877317A (en) 1993-12-28 1999-03-02 Pharmacia & Upjohn Company Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
CN1265660A (zh) * 1997-08-15 2000-09-06 辉瑞产品公司 2-(4-芳基或杂芳基-哌嗪-1-基甲基)-1h-吲哚衍生物
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
PT1443046E (pt) 2001-10-09 2009-02-26 Nisshin Pharma Inc Novas 4-(2-furoil)aminopiperidinas, produtos intermédios para a sua síntese, processos para a sua produção e utilização das mesmas em medicina
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030236259A1 (en) 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
CN1628109A (zh) 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基-与杂芳基-哌嗪
EP1476428B1 (de) 2002-02-22 2010-11-17 Pharmacia & Upjohn Company LLC Pyridylsulfon-derivate als 5-ht6 rezeptor liganden
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
AU2003272892A1 (en) * 2002-09-26 2004-04-19 Mandom Corporation Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1608629A1 (de) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzylpyridazinone als inhibitoren der reversen transkriptase
AU2003239845A1 (en) 2003-05-07 2004-11-26 Ifac Gmbh And Co.Kg Compositions for the targetted release of fragrances and aromas
CA2524498C (en) 2003-05-08 2012-01-24 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
NZ545265A (en) 2003-07-30 2009-11-27 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
EP1653969A4 (de) 2003-08-07 2006-12-20 Japan Tobacco Inc Pyrrolo 1,2-b pyridazin-derivate
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
WO2005077914A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS
CA2559552A1 (en) 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CN101005842A (zh) 2004-05-28 2007-07-25 弗特克斯药品有限公司 蕈毒碱性受体调节剂
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
HUE039584T2 (hu) 2004-10-29 2019-01-28 Kalypsys Inc PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
EP1902046B1 (de) 2005-06-20 2009-12-02 Schering Corporation Als antagonisten von histamin h3 geeignete piperidinderivate
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
MX2009001498A (es) 2006-08-15 2009-02-18 Hoffmann La Roche Derivados de fenilo, piridina y quinolina.
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
CA2683111A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
JP2010525013A (ja) * 2007-04-23 2010-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしてのピリジン誘導体
US8299257B2 (en) * 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 5−ht6受容体アンタゴニストとしての置換された6−(1−ピペラジニル)−ピリダジン類
CN102171189B (zh) 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶

Also Published As

Publication number Publication date
ZA200803668B (en) 2009-09-30
US9468640B2 (en) 2016-10-18
KR101351910B1 (ko) 2014-01-16
CN101291925A (zh) 2008-10-22
EP1943242B1 (de) 2011-01-12
EA200801184A1 (ru) 2008-08-29
US20170022181A1 (en) 2017-01-26
TWI399373B (zh) 2013-06-21
WO2007048779A1 (en) 2007-05-03
NO20082350L (no) 2008-07-01
HRP20110226T1 (hr) 2011-05-31
EA015681B1 (ru) 2011-10-31
SI1943242T1 (sl) 2011-05-31
HN2008000646A (es) 2011-02-16
AU2006307930A1 (en) 2007-05-03
US8940743B2 (en) 2015-01-27
AP2607A (en) 2013-03-05
EP1943242A1 (de) 2008-07-16
PL1943242T3 (pl) 2011-06-30
ES2359020T3 (es) 2011-05-17
DK1943242T3 (da) 2011-04-26
GT200800033A (es) 2009-08-20
JO2769B1 (en) 2014-03-15
US9751860B2 (en) 2017-09-05
DE602006019624D1 (de) 2011-02-24
US20080227791A1 (en) 2008-09-18
MY145609A (en) 2012-03-15
NZ566785A (en) 2010-03-26
CA2623160A1 (en) 2007-05-03
CR10020A (es) 2009-01-16
CA2623160C (en) 2013-10-15
AP2008004441A0 (en) 2008-04-30
PT1943242E (pt) 2011-04-06
RS51674B (sr) 2011-10-31
JP2009514815A (ja) 2009-04-09
US20150141432A1 (en) 2015-05-21
KR20080067658A (ko) 2008-07-21
AU2006307930B2 (en) 2011-10-06
CY1111977T1 (el) 2015-11-04
UA94058C2 (ru) 2011-04-11
ECSP088396A (es) 2008-05-30
CN101291925B (zh) 2013-04-10
BRPI0617787A2 (pt) 2009-12-01
AR058151A1 (es) 2008-01-23
JP5140598B2 (ja) 2013-02-06
IL191016A (en) 2013-10-31
TW200732321A (en) 2007-09-01
HK1124317A1 (en) 2009-07-10

Similar Documents

Publication Publication Date Title
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EP2049110A4 (de) Verbrückte diazepanorexin-rezeptorantagonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DE602007009305D1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EP1915372A4 (de) Indolderivate als crth2-rezeptorantagonisten
EP2170064A4 (de) 6,5-pyrrolopiperidin-tachykinin-rezeptorantagonisten
IL189453A0 (en) Carboxamide derivatives as muscarinic receptor antagonists
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DK1893603T3 (da) Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister
ATE486070T1 (de) Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
ATE423118T1 (de) Pyrazolopyridinderivate als inhibitoren der kinase 1 des beta-adrenergen rezeptors
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
EP1898905A4 (de) Hydroisoindolin-tachykinin-rezeptor-antagonisten
ATE553108T1 (de) Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1943242

Country of ref document: EP